{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"149","upperLimit":"466","value":"228"},{"comment":"Upper limit not reached due to lack of events","groupId":"OG001","lowerLimit":"245","upperLimit":"NA","value":"619"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"progression-free survival (PFS), defined as the time from randomization to the date the International Myeloma Working Group (IMWG) criteria for disease progression is met. If a patient initiates another anti-cancer treatment prior to disease progression, they will be censored at the date of initiation of this treatment. Patients will be randomized to treatment using the Pocock-Simon algorithm balancing the distribution of the following stratification factors between the two treatment arms: 1) ISS 1-2 disease vs. ISS 3 disease (current ISS stage based off screening beta 2 microglobulin and albumin) 2) High risk cytogenetics features: yes vs. no High risk cytogenetics features include: del(1p), gain of 1q, t(4;14), t(14;16), t(14; 20), del(17p) 3) Prior treatment with a proteasome inhibitor: yes vs. no","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Phase II Arm I (Pomalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib)"}],"paramType":"MEDIAN","populationDescription":"All eligible phase 2 patients were included in this analysis","reportingStatus":"POSTED","timeFrame":"3 years","title":"Progression Free Survival (PFS) (Phase II)","type":"PRIMARY","unitOfMeasure":"days"}